AstraZeneca plc (LON:AZN) shot up 0.5% during trading on Monday after Credit Suisse Group upgraded the stock from a neutral rating to an outperform rating. Credit Suisse Group now has a GBX 5,800 price target on the stock, up from their previous price target of GBX 4,800. AstraZeneca plc traded as high as GBX 5,251.04 ($69.77) and last traded at GBX 5,155 ($68.50). 2,029,967 shares changed hands during trading, a decline of 20% from the average session volume of 2,541,130 shares. The stock had previously closed at GBX 5,127 ($68.12).
A number of other equities research analysts have also issued reports on AZN. UBS AG set a GBX 5,150 ($68.43) target price on AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 27th. J P Morgan Chase & Co set a GBX 4,200 ($55.81) target price on AstraZeneca plc and gave the company a “neutral” rating in a research report on Wednesday, August 9th. Barclays PLC reissued an “overweight” rating and issued a GBX 5,500 ($73.08) target price on shares of AstraZeneca plc in a research report on Monday, August 7th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,600 ($74.41) target price on shares of AstraZeneca plc in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC lifted their target price on AstraZeneca plc from GBX 4,900 ($65.11) to GBX 5,100 ($67.77) and gave the company a “hold” rating in a research report on Monday. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. AstraZeneca plc has a consensus rating of “Hold” and an average price target of GBX 5,172.64 ($68.73).
In other news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($58.07) per share, for a total transaction of £1,704.30 ($2,264.55).
The stock’s market capitalization is GBX 65.40 billion. The stock’s 50 day moving average is GBX 4,859.28 and its 200-day moving average is GBX 4,907.26.
TRADEMARK VIOLATION WARNING: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/10/18/astrazeneca-plc-azn-shares-up-0-5-following-analyst-upgrade.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.